Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. 1997

D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

A novel class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position has been discovered. Four of these thrombin inhibitors (13b,c,e and 14d) showed nanomolar potency (Ki 0.8-12 nM), 300-1500-fold selectivity for thrombin compared with trypsin, and good oral bioavailability (F = 40-76%) in rats or dogs. The neutral P1 was expected to increase metabolic stability and oral absorption. Identification of this novel aminopyridyl group at P1 was a key step in our search for a clinical candidate.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin

Related Publications

D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
November 1996, Journal of medicinal chemistry,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
November 2006, Bioorganic & medicinal chemistry letters,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
September 1998, Bioorganic & medicinal chemistry letters,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
June 2004, Bioorganic & medicinal chemistry letters,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
May 2000, Journal of medicinal chemistry,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
July 2022, ACS medicinal chemistry letters,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
November 1999, European journal of medicinal chemistry,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
August 2003, Journal of medicinal chemistry,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
March 2000, Acta crystallographica. Section D, Biological crystallography,
D M Feng, and S J Gardell, and S D Lewis, and M G Bock, and Z Chen, and R M Freidinger, and A M Naylor-Olsen, and H G Ramjit, and R Woltmann, and E P Baskin, and J J Lynch, and R Lucas, and J A Shafer, and K B Dancheck, and I W Chen, and S S Mao, and J A Krueger, and T R Hare, and A M Mulichak, and J P Vacca
April 1999, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!